HF-158K1 by HighField Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

The MSOs Are Quite Risky

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

February 3, 2024

Combining health data with whole genome sequence data in cancer patients can help doctors provide more tailored care

Researchers evaluated the impact of integrating whole-genome sequencing data with clinical outcomes across 13,880 tumors from 33 cancer types, assessing precision care potentials within the

January 16, 2024

Radiopharmaceutical biotech Radionetics in fundraising mode with $54.2M so far

Radionetics Oncology is in the midst of a fundraising drive worth $68.7 million, with the California-based company having raised $54.2 million so far, per an

August 17, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.